日本新薬 has announced a lower-profit forecast because the sales launch date for its new product remains undecided. Factors including an increase in the cost ratio resulting from drug price revisions are said to have had an impact.
In its pharmaceutical business, 日本新薬 is said to have generated higher revenue from treatments for pulmonary hypertension, a rare disease, and epileptic seizures, as well as protein products among its functional foods.
Meanwhile, reports say that the undecided launch date for the new product and an increase in the cost ratio resulting from drug price revisions have been cited as factors behind the lower-profit forecast.
Accordingly, the company’s future earnings outlook is positioned as potentially subject to changes depending on the launch timing of the new product and developments in drug price revisions.